BioCentury | Jun 8, 2015
Clinical News

GBS-NN: Phase I started

MinervaX began a double-blind, placebo-controlled, dose-escalation, U.K. Phase I trial to evaluate 3 dose levels of GBS-NN with or without an Alhydrogel adjuvant in up to 310 healthy adult female volunteers. MinervaX ApS , Hellerup, Denmark...
BioCentury | Aug 11, 2014
Product Development

Internalizing outcomes

Proteus Digital Health Inc. hopes its Helius computer-enabled ingestible sensor system can deliver real-time monitoring of oral medication outcomes. The company's challenges are to convince payers that the added cost of the system is justified...
BioCentury | Feb 17, 2014
Finance

Funding the 3X3 plan

...an IPO wasn't something we wanted to do yet." Melinta was founded in 2001 as Rib-X Pharmaceuticals Inc....
BioCentury | Feb 11, 2014
Financial News

Antibiotics play Melinta raises about $35 million

...Partners. New investor Falcon Flight participated along with undisclosed existing and new investors. Melinta (formerly Rib-X Pharmaceuticals Inc....
BioCentury | Sep 23, 2013
Company News

Acusphere management update

...Mark Leuchtenberger as president, CEO and a director, formerly president, CEO and a director of Rib-X Pharmaceuticals Inc....
BioCentury | May 27, 2013
Clinical News

IV delafloxacin: Phase III started

...The start triggered a $500,000 milestone payment to Ligand Pharmaceuticals Inc. (NASDAQ:LGND, La Jolla, Calif.). Rib-X...
...CyDex Pharmaceuticals Inc. , which Ligand acquired in January 2011 (see BioCentury, Jan. 31, 2011) Rib-X Pharmaceuticals Inc....
BioCentury | Apr 8, 2013
Company News

Rib-X board of directors update

Rib-X Pharmaceuticals Inc. , New Haven, Conn. Business: Infectious Appointed: Thomas Koestler, a director, as chairman; he replaces Mary Szela who becomes CEO WIR Staff Infectious...
BioCentury | Apr 8, 2013
Finance

Company builder

...Company builder Several months after Vatera Holdings became Rib-X Pharmaceuticals Inc. 's biggest backer, the firm has now...
...companies for the long term. While an IPO is always a possibility, with Vatera's backing Rib-X...
...over as Rib-X's CEO last week. Her predecessor, Mark Leuchtenberger, left to pursue other opportunities. Rib-X...
BioCentury | Apr 8, 2013
Company News

Rib-X management update

Rib-X Pharmaceuticals Inc. , New Haven, Conn. Business: Infectious Hired: Michael Kenston as chief commercial officer, a newly created position, formerly VP of commercial analysis at Reata Pharmaceuticals Inc. ; Eugene Sun as EVP of R&D,...
BioCentury | Apr 3, 2013
Company News

Rib-X names new CEO

...of Abbott Laboratories (NYSE:ABT) -- now AbbVie Inc. (NYSE:ABBV). She replaces Mark Leuchtenberger, who left Rib-X...
...remain a director. Koestler is the executive director at Vatera Holdings, Rib-X's majority shareholder. Additionally, Rib-X...
...is partnered with Abbott under a 2010 deal. The management changes come several months after Rib-X...
Items per page:
1 - 10 of 107
BioCentury | Jun 8, 2015
Clinical News

GBS-NN: Phase I started

MinervaX began a double-blind, placebo-controlled, dose-escalation, U.K. Phase I trial to evaluate 3 dose levels of GBS-NN with or without an Alhydrogel adjuvant in up to 310 healthy adult female volunteers. MinervaX ApS , Hellerup, Denmark...
BioCentury | Aug 11, 2014
Product Development

Internalizing outcomes

Proteus Digital Health Inc. hopes its Helius computer-enabled ingestible sensor system can deliver real-time monitoring of oral medication outcomes. The company's challenges are to convince payers that the added cost of the system is justified...
BioCentury | Feb 17, 2014
Finance

Funding the 3X3 plan

...an IPO wasn't something we wanted to do yet." Melinta was founded in 2001 as Rib-X Pharmaceuticals Inc....
BioCentury | Feb 11, 2014
Financial News

Antibiotics play Melinta raises about $35 million

...Partners. New investor Falcon Flight participated along with undisclosed existing and new investors. Melinta (formerly Rib-X Pharmaceuticals Inc....
BioCentury | Sep 23, 2013
Company News

Acusphere management update

...Mark Leuchtenberger as president, CEO and a director, formerly president, CEO and a director of Rib-X Pharmaceuticals Inc....
BioCentury | May 27, 2013
Clinical News

IV delafloxacin: Phase III started

...The start triggered a $500,000 milestone payment to Ligand Pharmaceuticals Inc. (NASDAQ:LGND, La Jolla, Calif.). Rib-X...
...CyDex Pharmaceuticals Inc. , which Ligand acquired in January 2011 (see BioCentury, Jan. 31, 2011) Rib-X Pharmaceuticals Inc....
BioCentury | Apr 8, 2013
Company News

Rib-X board of directors update

Rib-X Pharmaceuticals Inc. , New Haven, Conn. Business: Infectious Appointed: Thomas Koestler, a director, as chairman; he replaces Mary Szela who becomes CEO WIR Staff Infectious...
BioCentury | Apr 8, 2013
Finance

Company builder

...Company builder Several months after Vatera Holdings became Rib-X Pharmaceuticals Inc. 's biggest backer, the firm has now...
...companies for the long term. While an IPO is always a possibility, with Vatera's backing Rib-X...
...over as Rib-X's CEO last week. Her predecessor, Mark Leuchtenberger, left to pursue other opportunities. Rib-X...
BioCentury | Apr 8, 2013
Company News

Rib-X management update

Rib-X Pharmaceuticals Inc. , New Haven, Conn. Business: Infectious Hired: Michael Kenston as chief commercial officer, a newly created position, formerly VP of commercial analysis at Reata Pharmaceuticals Inc. ; Eugene Sun as EVP of R&D,...
BioCentury | Apr 3, 2013
Company News

Rib-X names new CEO

...of Abbott Laboratories (NYSE:ABT) -- now AbbVie Inc. (NYSE:ABBV). She replaces Mark Leuchtenberger, who left Rib-X...
...remain a director. Koestler is the executive director at Vatera Holdings, Rib-X's majority shareholder. Additionally, Rib-X...
...is partnered with Abbott under a 2010 deal. The management changes come several months after Rib-X...
Items per page:
1 - 10 of 107